

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Meflosyl 5% Solution for Injection

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

#### **Active substance:**

Flunixin (as flunixin meglumine 83 mg)	50 mg
----------------------------------------	-------

#### **Excipients:**

Phenol	5 mg
Sodium formaldehyde sulfoxylate dihydrate	3.3 mg
Disodium edetate dihydrate	0.1 mg

For the full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Solution for injection.

A clear, colourless to faintly yellow liquid, visually free from particles.

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Horses.

#### **4.2 Indications for use, specifying the target species**

For the alleviation of inflammation and pain associated with musculo-skeletal disorders and for the alleviation of visceral pain associated with colic.

#### **4.3 Contraindications**

Do not exceed the recommended dose or duration of treatment.

Do not administer to pregnant mares.

Do not use in known cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding.

#### **4.4 Special warnings for each target species**

Non steroidal anti-inflammatory drugs are not permitted under the Rules of Racing and under rules governing other competitive events. The Royal College of Veterinary Surgeons has given advice to the veterinary profession regarding the use of anti-inflammatory drugs in competing horses. It states that if a veterinarian recommends the discontinuation of any such drug less than 8 days before racing, he should feel sure that he has catered for all but the most exceptional case.

#### **4.5 Special precautions for use**

i) Special precautions for use in animals

Intra-arterial injection should be avoided.

Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.

Avoid use in hypovolaemic animals, except in the case of endotoxaemia or septic shock.

It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). The product may cause an allergic reaction in people sensitised to NSAIDs.

People with known hypersensitivity to NSAIDs should avoid contact with the product. Hypersensitivity reactions may be serious.

To avoid possible sensitisation reactions and/or skin irritation, avoid contact with skin. Gloves should be worn during application. Wash hands after use. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

This product may cause eye irritation. Avoid contact with eyes. In the case of accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.

#### **4.6 Adverse reactions (frequency and seriousness)**

Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). Untoward effects include gastro-intestinal irritation, ulceration and in dehydrated or hypovolaemic animals, potential for renal damage.

#### **4.7 Use during pregnancy, lactation or lay**

Do not use in pregnant mares. Safety studies in pregnant mares have not been conducted.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Monitoring of drug compatibility is required in case of adjunctive therapy. Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Concurrent administration of potentially nephrotoxic drugs should be avoided.

#### **4.9 Amounts to be administered and administration route**

For intravenous administration.

For use in musculo-skeletal disorders, the recommended dose rate is 1.1 mg flunixin/kg bodyweight, equivalent to 1 ml per 45 kg, once daily for up to 5 days depending on clinical response.

For use in equine colic, the recommended dose rate is 1.1 mg flunixin/kg bodyweight, equivalent to 1 ml per 45 kg. Treatment may be repeated once or twice if colic recurs.

For the treatment of endotoxaemia or shock-associated with gastric torsion and with other conditions in which the circulation of blood to the gastro-intestinal tract is compromised: 0.25 mg/kg (= 1 ml per 200 kg bodyweight) administered every 6-8 hours.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Overdosage studies in the target species have shown the product to be well tolerated. Overdosage is associated with gastro-intestinal toxicity.

#### **4.11 Withdrawal periods**

Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Flunixin meglumine is a potent, non narcotic, non steroidal analgesic agent with anti-inflammatory, antipyretic and anti-endotoxic activity.

Flunixin meglumine is a potent inhibitor of cyclo-oxygenase and thereby of the endogenous production of prostaglandins.

Flunixin has no influence on natural or per injection administered prostaglandin F<sub>2</sub>-alpha.

It has been demonstrated that flunixin has an anti-endotoxin activity, in particular against the effects of endotoxins formed by *E Coli*.

### **5.2 Pharmacokinetic properties**

#### Absorption/Elimination

Studies in horses have shown that onset of activity occurs within 2 hours (= 15 to 60 minutes) after parenteral administration when used in musculo-skeletal disorders.

Peak response occurs between 12 and 16 hours and the duration of activity is 24-36 hours (30-40 hours).

When used in equine colic, studies have shown alleviation of pain within 15 minutes (intravenous).

The plasma half-life in horse-serum is 1.6 hours following a single dose of 1.1 mg/kg. Measurable amounts are detectable in horse plasma at eight hours post injection.

Flunixin is mainly excreted via the bile. A minor part is eliminated via the urine.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Phenol  
Sodium formaldehyde sulfoxylate dihydrate  
Disodium Edetate Dihydrate  
Propylene Glycol  
Diolamine  
Hydrochloric Acid  
Hydrochloric Acid or Sodium Hydroxide  
Water for Injections

### **6.2 Major incompatibilities**

Do not mix with other medications prior to administration.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf-life after first opening the immediate packaging: 28 days.

### **6.4 Special precautions for storage**

Do not store above 25°C.  
Protect from light  
Following withdrawal of the first dose use the product within 28 days.  
Discard unused product.

### **6.5 Nature and composition of immediate packaging**

Colourless type I glass vials of 50 and 100 ml. The vials are closed with rubber stoppers and sealed with aluminium caps.  
Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

## **8. MARKETING AUTHORISATION NUMBER**

Vm: 42058/4085

## **9. DATE OF FIRST AUTHORISATION**

27 March 1998

## **10. DATE OF REVISION OF THE TEXT**

September 2020

Approved 04 September 2020

